Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

Status unconfirmed · Phase 2

Conditions studied: Leukemia, Lymphoma

In brief

RATIONALE: Biological therapies such as denileukin diftitox may be able to deliver cancer-killing substances directly to non-Hodgkin's lymphoma cells. PURPOSE: Phase II trial to study the effectiveness of denileukin diftitox in treating patients who have non-Hodgkin's lymphoma.

Key facts

Study ID

NCT00026429

Run by

Pharmatech Oncology

Starts

2001-01-01

Last updated by the study team

2013-12-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Nassau Hematology/Oncology PC — Lake Success, New York, United States
• Coastal Cancer Center — Myrtle Beach, South Carolina, United States
• Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group — Memphis, Tennessee, United States
• ION/Pharmatech Network — Pomona, California, United States
• Cancer and Blood Institute of the Desert — Rancho Mirage, California, United States
• Missouri Cancer Care, P.C. — Saint Charles, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.